Spruce Biosciences Announces Acceptance of Abstract for Presentation at ENDO 2022 Annual Conference

Rhea-AI Summary

Spruce Biosciences (NASDAQ: SPRB) announced an abstract acceptance for a poster presentation at the 104th Annual Meeting of the Endocrine Society (ENDO 2022) in Atlanta, GA, scheduled for June 11-14, 2022. The presentation will cover survey results assessing patient perceptions on glucocorticoid treatment for congenital adrenal hyperplasia (CAH). Key details include the session date of June 11, 2022, from 1:00 p.m. to 3:00 p.m. ET, presented by Dr. Chris N. Barnes. The company aims to develop non-steroidal therapies for CAH and is also exploring treatments for polycystic ovary syndrome (PCOS).

Positive

• Abstract accepted for presentation at a major medical conference, potentially enhancing visibility among stakeholders.
• Focus on unmet needs in rare endocrine disorders, demonstrating a commitment to addressing significant health issues.

Negative

• None.

SAN FRANCISCO--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for poster presentation at the 104^th Annual Meeting of the Endocrine Society (ENDO 2022) taking place June 11-14, 2022, in Atlanta, GA. In a recorded presentation, the company will highlight results from a recent survey of individuals living with congenital adrenal hyperplasia (CAH) to assess their perceptions around glucocorticoid treatment regimens and glucocorticoid-associated side effects.

Details are as follows:

Title: (P079) A Survey of Patients Living with CAH Assessing Their Perceptions on Glucocorticoid Regimen and Glucocorticoid-Associated Side Effects
Session Date & Time: 1:00p.m. - 3:00p.m. ET on June 11, 2022
Presenter: Dr. Chris N. Barnes
Authors: Dr. Chris N. Barnes, Dr. Rosh Dias, Melodie Feather and Nina Sherpa-Pine

The poster will be on display during the conference in ENDO 2022's virtual poster hall starting on June 11, at 10:00 a.m. ET. Access more information about ENDO 2022 at https://endo2022.endocrine.org.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit www.sprucebiosciences.com and follow us on Twitter @Spruce_Bio, LinkedIn, Facebook and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220531005203/en/

Media Contact

Will Zasadny

Canale Communications

(619) 961-8848

will.zasadny@canalecomm.com

media@sprucebiosciences.com

Investors

Xuan Yang

Solebury Trout

(415) 971-9412

xyang@soleburytrout.com

investors@sprucebiosciences.com

Source: Spruce Biosciences, Inc.

FAQ

What is the significance of the poster presentation at ENDO 2022 for Spruce Biosciences (SPRB)?

The poster presentation at ENDO 2022 allows Spruce Biosciences to share critical survey findings about patient perceptions on glucocorticoid treatments for CAH, enhancing their visibility in the scientific community.

When will the poster presentation by Spruce Biosciences (SPRB) take place?

The poster presentation will occur on June 11, 2022, from 1:00 p.m. to 3:00 p.m. ET during the ENDO 2022 conference.

What disease target is Spruce Biosciences (SPRB) focusing on with their therapies?

Spruce Biosciences is focusing on therapies for congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS).

Who is presenting the abstract for Spruce Biosciences (SPRB) at ENDO 2022?

Dr. Chris N. Barnes will present the abstract at ENDO 2022.